Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Top Cited Papers
- 8 February 2012
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (8) , 3089-3094
- https://doi.org/10.1073/pnas.1115941109
Abstract
Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe hRSV infections. Palivizumab, as most anti-F antibodies so far described, recognizes an epitope that is shared by the two conformations in which hRSV_F can fold, the metastable prefusion form and the highly stable postfusion conformation. We now describe a unique class of antibodies specific for the prefusion form of this protein that account for most of the neutralizing activity of either a rabbit serum raised against a vaccinia virus recombinant expressing hRSV_F or a human Ig preparation (Respigam), which was used for prophylaxis before Palivizumab. These antibodies therefore offer unique possibilities for immune intervention against hRSV, and their production should be assessed in trials of hRSV vaccines.Keywords
This publication has 38 references indexed in Scilit:
- Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing EpitopesJournal of Virology, 2011
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersProceedings of the National Academy of Sciences, 2011
- Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State Is Triggered by Exposure to Low-Molarity BufferJournal of Virology, 2011
- Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion GlycoproteinJournal of Virology, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Structural basis of respiratory syncytial virus neutralization by motavizumabNature Structural & Molecular Biology, 2010
- Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseNature Medicine, 2008
- Electron Cryomicroscopy Reveals Different F1+F2 Protein States in Intact Parainfluenza VirionsJournal of Virology, 2008
- Structural basis of viral invasion: lessons from paramyxovirus FCurrent Opinion in Structural Biology, 2007
- Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopyProceedings of the National Academy of Sciences, 2006